


# PH is a family of rare genetic disorders causing hepatic oxalate overproduction that can result in life-threatening kidney damage<sup>1</sup>



## Liver enzyme deficiency

causes metabolic pathway dysregulation and the overproduction of glyoxylate. LDH catalyzes the final common step in this pathway, resulting in an overproduction of oxalate<sup>1-4</sup>

## Renal damage

is caused by CaOx crystals that form kidney and bladder stones and nephrocalcinosis, which results in progressive kidney deterioration, CKD, and systemic oxalosis<sup>2,5</sup>


Abbreviations: CaOx, calcium oxalate; CKD, chronic kidney disease; LDH, lactate dehydrogenase.

1. Cochat P, Rumsby G. *N Engl J Med*. 2013;369(7):649-658. 2. Lai C, et al. *Mol Ther*. 2018;26(8):1983-1995. 3. Belostotsky R, et al. *J Mol Med (Berl)*. 2012;90(12):1497-1504.

4. Riedel TJ, et al. *Biochim Biophys Acta*. 2012;1822(10):1544-1552. 5. Hoppe B, Martin-Higueras C. *Curr Opin Pediatr*. 2020;32(2):273-283.


# Calcium oxalate crystals combine to form stones in PH

*Hyperoxaluria is a condition defined by increased urinary excretion of oxalate<sup>1</sup>*




**Oxalate<sup>2</sup>** is a metabolic end product, which can also be ingested through food, that is of no known use to the body<sup>1,3</sup>

When too much oxalate accumulates in the kidneys, it binds with calcium to form **calcium oxalate** (CaOx) crystals<sup>4,5</sup>



CaOx crystals aggregate to form **stones** in the kidneys and urinary tract, and also distribute throughout the kidney tissue, causing **nephrocalcinosis<sup>3</sup>**




◆ = calcium oxalate crystal

● = stone

1. Bhasin B, et al. *World J Nephrol.* 2015;4(2):235-244. 2. National Center for Biotechnology Information. PubChem Database. Oxalate, CID=71081. <https://pubchem.ncbi.nlm.nih.gov/compound/71081>. Accessed June 11, 2020. 3. Danpure CJ, Rumsby G. *Expert Rev Mol Med.* 2004;6(1):1-16. 4. Dindo M, et al. *Urolithiasis.* 2019;47(1):67-78. 5. Lai C, et al. *Mol Ther.* 2018;26(8):1983-1995. 6. Hochrein O, et al. *Z Anorg Allg Chem.* 2008;634(11):1826-1829. 7. National Center for Biotechnology Information. PubChem Database. Calcium oxalate, CID=33005. <https://pubchem.ncbi.nlm.nih.gov/compound/33005>. Accessed June 11, 2020.

# As PH advances, progressive nephrocalcinosis and renal damage may lead to end-stage renal disease and systemic oxalosis

- 1 Progressive calcification (**nephrocalcinosis**), inflammation, and interstitial fibrosis lead to **ESRD**<sup>1,2,\*</sup>



- 2 When glomerular filtration rate drops below 30-45 mL/min, oxalate is no longer adequately filtered by the kidneys, resulting in **systemic oxalosis**<sup>2</sup>


◆ CaOx crystals are deposited in tissue throughout the body, especially the skeleton<sup>3</sup>

Bone fractures, bone deformation, inhibited bone growth, anemia, severe pain<sup>4,5</sup>




CaOx deposits in the bone<sup>6</sup>

Retinopathy<sup>4,5</sup>




Retinal CaOx deposits<sup>6</sup>

Skin ulcers, nodules<sup>4,5</sup>



Crystal deposits at finger tip<sup>6</sup>

Cardiomyopathy, conduction disturbances<sup>4,5</sup>



CaOx deposits in the heart<sup>6</sup>

Abbreviations: CaOx, calcium oxalate; ESRD, end-stage renal disease.

\*Case courtesy of Dr Ian Bickle, Radiopaedia.org, rID: 45927.

1. Lai C, et al. *Mol Ther*. 2018;26(8):1983-1995. 2. Harambat J, et al. *Int J Nephrol*. 2011;2011:864580. 3. Cochat P, Rumsby G. *N Engl J Med*. 2013;369(7):649-658. 4. Salido E, et al. *Biochim Biophys Acta*. 2012;1822(9):1453-1464. 5. Sas DJ, et al. *Urolithiasis*. 2019;47(1):79-89. 6. Hoppe B, et al. *Kidney Int*. 2009;75(12):1264-1271.